Dosage errors: the boom of Ozempic and Wegovy triggered calls to poisoning centers

The rapid rise in the use of semaglutide—marketed under brand names such as Ozempic and Wegovy—for chronic weight management has led to an unexpected surge in calls to poison control centers across the United States. Initially introduced as a treatment for type 2 diabetes, the drug's popularity expanded significantly when it was approved for weight loss purposes. This shift brought about a new challenge: a dramatic increase in reports of adverse effects linked to improper usage, highlighting a critical need for improved patient education on safe administration practices. Before 2021, U.S. poison control centers typically received between 1,000 and 1,500 annual cases related to GLP-1 receptor agonists. However, this number changed drastically around mid-2021, following the FDA’s approval of semaglutide for weight management. By 2023, these centers had recorded over 8,000 calls annually, making semaglutide the most frequently cited medication in such incidents. The sudden spike underscores how the drug’s widespread adoption for obesity treatment has reshaped public health concerns. Research conducted by Jordan Miller and Professor David Han from the University of Texas at San Antonio (UTSA) revealed that the majority of these incidents were not due to intentional misuse but rather accidental therapeutic errors and dosing mistakes made by patients at home. Their findings emphasize that many users misunderstood how the medication works and failed to follow the necessary guidelines for its administration. According to statistical analysis carried out in collaboration with experts Robert S. Miller and Shawn M. Varney from the Long School of Medicine, two common errors emerged in patient routines. First, many individuals began taking the medication daily instead of adhering to the required weekly schedule. Second, a significant portion of patients skipped the step-by-step dose escalation process, opting to inject the highest dose immediately without gradually increasing it over time. These combined mistakes—taking the medication more frequently than recommended and starting at maximum strength—led to numerous cases of poisoning symptoms. The study highlights how the expansion of semaglutide into the broader population seeking weight loss has altered both the nature and volume of emergency calls compared to its traditional use among diabetic patients. Researchers argue that enhancing public education throughout each stage of the prescription process—from initial medical consultation to pharmacy pickup—could largely prevent these incidents. This research project initially gained recognition at the UTSA Data Conference and quickly gained traction within the scientific community. Its conclusions were featured prominently in Significance, the flagship journal of the Royal Statistical Society and the American Statistician. The findings have sparked discussions about the importance of clear communication regarding medication use, especially when drugs transition from niche treatments to widely used therapies. As the demand for weight-loss medications continues to grow, healthcare providers and regulatory bodies face mounting pressure to ensure that patients receive comprehensive guidance on proper usage. The experience with semaglutide serves as a cautionary tale about the potential risks associated with rapid pharmaceutical adoption and the necessity of robust educational measures to mitigate unintended consequences.